You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetobemidone
Accession NumberDB06738
TypeSmall Molecule
GroupsApproved
DescriptionKetobemidone is a powerful opioid analgesic. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.
Structure
Thumb
Synonyms
Cetobemidona
Cetobemidone
Cetobemidonum
Cliradon
Cymidon
Ketobemidone
Ketodur
Ketogan
Ketorax
External Identifiers
  • UNII-PQS1L514CF
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CliradonPfizer
KetoganPfizer
KetoraxPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ketobemidone hydrochloride
Thumb
  • InChI Key: ALFGKMXHOUSVAD-UHFFFAOYSA-N
  • Monoisotopic Mass: 247.157228921
  • Average Mass: 247.3327
DBSALT000189
Categories
UNIIPQS1L514CF
CAS number469-79-4
WeightAverage: 247.3327
Monoisotopic: 247.157228921
Chemical FormulaC15H21NO2
InChI KeyInChIKey=ALFGKMXHOUSVAD-UHFFFAOYSA-N
InChI
InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3
IUPAC Name
1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one
SMILES
CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Aralkylamine
  • Phenol
  • Benzenoid
  • Gamma-aminoketone
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures.
PharmacodynamicsNot Available
Mechanism of actionKetobemidone (Cliradon, Ketogan, Ketodur, Cymidon, Ketorax, &c.) is a powerful opioid analgesic. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.
Related Articles
Absorption34% (oral), 44% (rectal)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Ketobemidone is mainly metabolised by conjugation of the phenolic hydroxyl group, and by N-desmethylation. Only about 13-24% is excreted unchanged after iv. administration.

SubstrateEnzymesProduct
Ketobemidone
Reduced ketobemidoneDetails
Ketobemidone
NorketobemidoneDetails
Ketobemidone
Ketobemidone N-oxideDetails
Norketobemidone
Not Available
Dihydroxy norketobemidoneDetails
Ketobemidone
Dihydroxy ketobemidoneDetails
Dihydroxy ketobemidone
Not Available
p-Hydroxymethoxy ketobemidoneDetails
Dihydroxy ketobemidone
Not Available
m-Hydroxymethoxy ketobemidoneDetails
Route of eliminationNot Available
Half lifePlasma half-life: 2.42 +/- 0.41 h (m +/- SD). Elimination half-life: 3.27 +/- 0.32 h
ClearanceNot Available
ToxicityBase: Rat Intravenous LD50: 10 mg/kg; Mouse Intravenous LD50: 14 mg/kg. Hydrochloride salt: Rat Oral LD50: 215 mg/kg; Rat Intravenous LD50: 40 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ketobemidone Action PathwayDrug actionSMP00690
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.9777
Caco-2 permeable+0.7753
P-glycoprotein substrateSubstrate0.8263
P-glycoprotein inhibitor INon-inhibitor0.6758
P-glycoprotein inhibitor IINon-inhibitor0.6722
Renal organic cation transporterInhibitor0.6578
CYP450 2C9 substrateNon-substrate0.8324
CYP450 2D6 substrateSubstrate0.6178
CYP450 3A4 substrateSubstrate0.6483
CYP450 1A2 substrateNon-inhibitor0.8062
CYP450 2C9 inhibitorNon-inhibitor0.889
CYP450 2D6 inhibitorInhibitor0.6678
CYP450 2C19 inhibitorNon-inhibitor0.9396
CYP450 3A4 inhibitorNon-inhibitor0.6532
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9154
Ames testNon AMES toxic0.882
CarcinogenicityNon-carcinogens0.8277
BiodegradationNot ready biodegradable0.9801
Rat acute toxicity2.5982 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6132
hERG inhibition (predictor II)Inhibitor0.6146
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility3.01 mg/mLALOGPS
logP2.01ALOGPS
logP2.49ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)9.44ChemAxon
pKa (Strongest Basic)8.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity73.12 m3·mol-1ChemAxon
Polarizability28.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Bondesson U, Hartvig P, Danielsson B: Quantitative determination of the urinary excretion of ketobemidone and four of its metabolites after intravenous and oral administration in man. Drug Metab Dispos. 1981 Jul-Aug;9(4):376-80. [PubMed:6114838 ]
  2. Anderson P, Arner S, Bondesson U, Boreus LO, Hartvig P: Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. Eur J Clin Pharmacol. 1981 Feb;19(3):217-23. [PubMed:7215421 ]
External Links
ATC CodesN02AG02N02AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (83.4 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ketobemidone.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Ketobemidone.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ketobemidone.
AbirateroneThe serum concentration of Ketobemidone can be increased when it is combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Ketobemidone.
AcepromazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ketobemidone.
AcetazolamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ketobemidone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Ketobemidone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ketobemidone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ketobemidone.
AlimemazineAlimemazine may increase the hypotensive activities of Ketobemidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ketobemidone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketobemidone.
AlvimopanThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amiloride.
AmiodaroneThe metabolism of Ketobemidone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Ketobemidone.
AmitriptylineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Ketobemidone which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketobemidone.
AmoxapineKetobemidone may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ketobemidone.
AmperozideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Ketobemidone.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Ketobemidone.
AprepitantThe serum concentration of Ketobemidone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.
ArmodafinilThe metabolism of Ketobemidone can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ketobemidone.
AtazanavirThe metabolism of Ketobemidone can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Ketobemidone can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ketobemidone.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Ketobemidone.
AzaperoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azaperone.
AzelastineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketobemidone.
AzosemideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Ketobemidone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ketobemidone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ketobemidone.
BenzphetamineBenzphetamine may increase the analgesic activities of Ketobemidone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Ketobemidone can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Ketobemidone.
BoceprevirThe metabolism of Ketobemidone can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Ketobemidone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ketobemidone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
BrimonidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketobemidone.
BrompheniramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketobemidone.
BuprenorphineBuprenorphine may decrease the analgesic activities of Ketobemidone.
BuprenorphineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketobemidone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketobemidone.
ButacaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ketobemidone.
ButorphanolButorphanol may decrease the analgesic activities of Ketobemidone.
ButorphanolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Canrenoic acid.
CapecitabineThe metabolism of Ketobemidone can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ketobemidone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ketobemidone.
CarisoprodolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carisoprodol.
CelecoxibThe metabolism of Ketobemidone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ketobemidone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketobemidone.
ChloramphenicolThe metabolism of Ketobemidone can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketobemidone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ketobemidone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketobemidone.
ChlorothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Ketobemidone.
ChlorphentermineChlorphentermine may increase the analgesic activities of Ketobemidone.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Ketobemidone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ketobemidone.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Ketobemidone can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Ketobemidone can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketobemidone.
CitalopramKetobemidone may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Ketobemidone can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Ketobemidone can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Ketobemidone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ketobemidone.
ClomipramineKetobemidone may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ketobemidone.
ClonazepamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonidine.
ClopidogrelThe metabolism of Ketobemidone can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketobemidone.
ClotrimazoleThe metabolism of Ketobemidone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketobemidone.
CobicistatThe metabolism of Ketobemidone can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketobemidone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketobemidone.
ConivaptanThe serum concentration of Ketobemidone can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Conivaptan.
CrizotinibThe metabolism of Ketobemidone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketobemidone.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Ketobemidone.
CyclosporineThe metabolism of Ketobemidone can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Ketobemidone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketobemidone.
DapoxetineKetobemidone may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Ketobemidone.
DarunavirThe metabolism of Ketobemidone can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Ketobemidone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ketobemidone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ketobemidone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ketobemidone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketobemidone.
DesipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ketobemidone.
DesmopressinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Detomidine.
DexamethasoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Ketobemidone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketobemidone.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Ketobemidone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketobemidone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ketobemidone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketobemidone.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.
DifenoxinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketobemidone.
DihydroergotamineThe metabolism of Ketobemidone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketobemidone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone.
DiltiazemThe metabolism of Ketobemidone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketobemidone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketobemidone.
DoramectinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doxepin.
DoxorubicinThe metabolism of Ketobemidone can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Ketobemidone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
DoxylamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ketobemidone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
DronedaroneThe metabolism of Ketobemidone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ketobemidone.
DrospirenoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ketobemidone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ketobemidone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Ketobemidone.
EfavirenzThe serum concentration of Ketobemidone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efonidipine.
EluxadolineKetobemidone may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ketobemidone.
EntacaponeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Entacapone.
EnzalutamideThe serum concentration of Ketobemidone can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Eplerenone.
ErythromycinThe metabolism of Ketobemidone can be decreased when combined with Erythromycin.
EscitalopramKetobemidone may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ketobemidone can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Ketobemidone can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketobemidone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketobemidone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etacrynic acid.
EthanolKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ketobemidone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Ketobemidone.
EthosuximideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ketobemidone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ketobemidone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketobemidone.
EtidocaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketobemidone.
EtoperidoneKetobemidone may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ketobemidone.
EtravirineThe serum concentration of Ketobemidone can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Felbamate.
FelodipineThe metabolism of Ketobemidone can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketobemidone.
FenfluramineKetobemidone may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketobemidone.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ketobemidone.
FexofenadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flibanserin.
FloxuridineThe metabolism of Ketobemidone can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Ketobemidone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketobemidone.
FlunarizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ketobemidone.
FluorouracilThe metabolism of Ketobemidone can be decreased when combined with Fluorouracil.
FluoxetineKetobemidone may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Ketobemidone can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketobemidone.
FluphenazineFluphenazine may increase the hypotensive activities of Ketobemidone.
FluphenazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketobemidone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ketobemidone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Ketobemidone can be decreased when combined with Fluvastatin.
FluvoxamineKetobemidone may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Ketobemidone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ketobemidone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ketobemidone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ketobemidone.
FurosemideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Furosemide.
Fusidic AcidThe serum concentration of Ketobemidone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketobemidone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ketobemidone is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Ketobemidone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ketobemidone.
GemfibrozilThe metabolism of Ketobemidone can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ketobemidone.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Ketobemidone.
GuanfacineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ketobemidone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketobemidone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketobemidone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ketobemidone.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Ketobemidone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketobemidone.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Ketobemidone.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ketobemidone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Ketobemidone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
HydroxyzineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Ketobemidone.
IdelalisibThe serum concentration of Ketobemidone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Iloperidone.
ImatinibThe metabolism of Ketobemidone can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Imipramine.
IndalpineKetobemidone may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Indapamide.
IndinavirThe metabolism of Ketobemidone can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ketobemidone.
IrbesartanThe metabolism of Ketobemidone can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Ketobemidone can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketobemidone.
IsoniazidThe metabolism of Ketobemidone can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Isosorbide.
IsradipineThe metabolism of Ketobemidone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Ketobemidone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Ketobemidone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketobemidone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ketobemidone.
KetoconazoleThe metabolism of Ketobemidone can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Ketobemidone is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lamotrigine.
LapatinibThe metabolism of Ketobemidone can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Ketobemidone can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ketobemidone.
LevocabastineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketobemidone.
LevomilnacipranKetobemidone may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketobemidone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ketobemidone.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Ketobemidone.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ketobemidone.
LofentanilThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lofentanil.
LopinavirThe metabolism of Ketobemidone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketobemidone.
LosartanThe metabolism of Ketobemidone can be decreased when combined with Losartan.
LovastatinThe metabolism of Ketobemidone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketobemidone.
Lu AA21004Ketobemidone may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Ketobemidone.
LuliconazoleThe serum concentration of Ketobemidone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ketobemidone can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ketobemidone.
MeclizineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ketobemidone.
MelperoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Ketobemidone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketobemidone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone.
MersalylThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Ketobemidone.
MesoridazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketobemidone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ketobemidone.
MethamphetamineMethamphetamine may increase the analgesic activities of Ketobemidone.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Ketobemidone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ketobemidone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ketobemidone.
MethazolamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketobemidone.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Ketobemidone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketobemidone.
MethsuximideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Ketobemidone.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketobemidone.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Ketobemidone.
MetolazoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone.
MetyrosineKetobemidone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone.
MifepristoneThe metabolism of Ketobemidone can be decreased when combined with Mifepristone.
MilnacipranKetobemidone may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
MirtazapineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ketobemidone.
MitotaneThe serum concentration of Ketobemidone can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Ketobemidone can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Ketobemidone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ketobemidone.
MoricizineMoricizine may increase the hypotensive activities of Ketobemidone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ketobemidone.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Ketobemidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.
NabiloneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nabilone.
NafcillinThe serum concentration of Ketobemidone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Ketobemidone.
NalbuphineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Ketobemidone can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Ketobemidone can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Ketobemidone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Ketobemidone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ketobemidone can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Ketobemidone can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Ketobemidone can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ketobemidone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ketobemidone.
NormethadoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Ketobemidone.
OlanzapineKetobemidone may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone.
OlaparibThe metabolism of Ketobemidone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Olopatadine.
OmeprazoleThe metabolism of Ketobemidone can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketobemidone.
OpiumThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Opium.
OrphenadrineKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ketobemidone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ketobemidone.
OsimertinibThe serum concentration of Ketobemidone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketobemidone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketobemidone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketobemidone.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ketobemidone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketobemidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketobemidone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ketobemidone.
PalbociclibThe serum concentration of Ketobemidone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketobemidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ketobemidone.
PantoprazoleThe metabolism of Ketobemidone can be decreased when combined with Pantoprazole.
ParaldehydeKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ketobemidone.
ParoxetineKetobemidone may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Ketobemidone can be decreased when combined with Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.
PentazocinePentazocine may decrease the analgesic activities of Ketobemidone.
PentazocineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ketobemidone.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Ketobemidone.
PerampanelThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Ketobemidone.
PerphenazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketobemidone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ketobemidone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Ketobemidone.
PhenytoinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketobemidone.
PioglitazoneThe metabolism of Ketobemidone can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ketobemidone.
PipotiazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ketobemidone.
PiretanideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pomalidomide.
PosaconazoleThe metabolism of Ketobemidone can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium Citrate.
PramipexoleKetobemidone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ketobemidone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketobemidone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ketobemidone.
PrimidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ketobemidone.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Ketobemidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Ketobemidone.
PromazinePromazine may increase the hypotensive activities of Ketobemidone.
PromazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Ketobemidone.
PromethazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Ketobemidone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketobemidone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketobemidone.
PropoxycaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ketobemidone.
PyrimethamineThe metabolism of Ketobemidone can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Ketobemidone can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketobemidone.
QuinethazoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Ketobemidone.
QuinineThe metabolism of Ketobemidone can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Ketobemidone can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ramelteon.
RamosetronKetobemidone may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Ketobemidone can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketobemidone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketobemidone.
RifabutinThe metabolism of Ketobemidone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ketobemidone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ketobemidone can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketobemidone.
RitonavirThe metabolism of Ketobemidone can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Romifidine.
RopiniroleKetobemidone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketobemidone.
RosiglitazoneThe metabolism of Ketobemidone can be decreased when combined with Rosiglitazone.
RotigotineKetobemidone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketobemidone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ketobemidone.
SaquinavirThe metabolism of Ketobemidone can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketobemidone.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ketobemidone.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketobemidone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ketobemidone.
SertralineKetobemidone may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Ketobemidone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketobemidone.
SildenafilThe metabolism of Ketobemidone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ketobemidone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ketobemidone can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Ketobemidone.
SorafenibThe metabolism of Ketobemidone can be decreased when combined with Sorafenib.
SpironolactoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Spironolactone.
St. John's WortThe serum concentration of Ketobemidone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Ketobemidone.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.
SulfadiazineThe metabolism of Ketobemidone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Ketobemidone can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Ketobemidone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketobemidone.
SuvorexantThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Suvorexant.
TamoxifenThe metabolism of Ketobemidone can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tasimelteon.
TelaprevirThe metabolism of Ketobemidone can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Ketobemidone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketobemidone.
TeriflunomideThe metabolism of Ketobemidone can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ketobemidone.
ThalidomideKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ketobemidone.
TheobromineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketobemidone.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Ketobemidone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketobemidone.
ThioridazineThioridazine may increase the hypotensive activities of Ketobemidone.
ThioridazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Thioridazine.
ThiotepaThe metabolism of Ketobemidone can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketobemidone.
TiagabineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiagabine.
TicagrelorThe metabolism of Ketobemidone can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Ketobemidone can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Ketobemidone.
TizanidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tizanidine.
TocilizumabThe serum concentration of Ketobemidone can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Ketobemidone can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Ketobemidone.
TolvaptanThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketobemidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ketobemidone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketobemidone.
TrazodoneKetobemidone may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketobemidone.
TriamtereneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketobemidone.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Ketobemidone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Ketobemidone.
TriflupromazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Ketobemidone.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Ketobemidone.
TrimethoprimThe metabolism of Ketobemidone can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Ketobemidone.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Ketobemidone.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ketobemidone.
UlaritideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Ketobemidone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ketobemidone.
ValsartanThe metabolism of Ketobemidone can be decreased when combined with Valsartan.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ketobemidone.
VenlafaxineThe metabolism of Ketobemidone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Ketobemidone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Vigabatrin.
VilazodoneKetobemidone may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Ketobemidone can be decreased when combined with Voriconazole.
VortioxetineKetobemidone may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ketobemidone.
XylazineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Xylazine.
ZafirlukastThe metabolism of Ketobemidone can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketobemidone.
ZiconotideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ziconotide.
ZimelidineKetobemidone may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Ketobemidone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ketobemidone.
ZonisamideThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketobemidone.
ZotepineThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketobemidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Kristensen K, Christensen CB, Christrup LL, Nielsen LC: The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4. [PubMed:8878254 ]
  2. Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5. [PubMed:8153059 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5. [PubMed:8153059 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Christensen CB: The opioid receptor binding profiles of ketobemidone and morphine. Pharmacol Toxicol. 1993 Dec;73(6):344-5. [PubMed:8153059 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Ebert B, Andersen S, Krogsgaard-Larsen P: Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995 Mar 10;187(3):165-8. [PubMed:7624018 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 31, 2010 15:02 / Updated on August 17, 2016 12:24